Journal
DRUGS OF TODAY
Volume 48, Issue 6, Pages 395-403Publisher
PROUS SCIENCE, SAU-THOMSON REUTERS
DOI: 10.1358/dot.2012.48.6.1825620
Keywords
Chronic kidney disease; Anemia; Erythropoietin; Erythropoiesis-stimulating agents; Peginesatide
Categories
Ask authors/readers for more resources
Anemia is a major complication in patients with chronic kidney disease, as the damaged kidney is unable to produce enough erythropoietin. Peginesatide (formerly known as Hematide (TM)) is a synthetic, peptide-based erythropoiesis-stimulating agent linked to polyethylene glycol. Based on extensive preclinical and clinical data substantiating the efficacy and safety of this agent, it was approved in the U.S. in March 2012 for the treatment of anemia due to chronic kidney disease in adult patients on dialysis. Peginesatide (Omontys (R)) was launched in the U.S. in April 2012.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available